Phreesia (PHR)
Market Price (2/21/2026): $12.78 | Market Cap: $766.9 MilSector: Health Care | Industry: Health Care Technology
Phreesia (PHR)
Market Price (2/21/2026): $12.78Market Cap: $766.9 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% | Weak multi-year price returns2Y Excs Rtn is -93%, 3Y Excs Rtn is -134% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1.9% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14% | |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -47% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0% | |
| Low stock price volatilityVol 12M is 48% | Key risksPHR key risks include [1] a history of cybersecurity incidents, Show more. | |
| Megatrend and thematic driversMegatrends include Cloud Computing, Fintech & Digital Payments, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -47% |
| Low stock price volatilityVol 12M is 48% |
| Megatrend and thematic driversMegatrends include Cloud Computing, Fintech & Digital Payments, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Show more. |
| Weak multi-year price returns2Y Excs Rtn is -93%, 3Y Excs Rtn is -134% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1.9% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0% |
| Key risksPHR key risks include [1] a history of cybersecurity incidents, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Revised Downward Organic Growth Guidance: Phreesia's management updated its fiscal year 2026 organic growth guidance to approximately 13%, a notable decrease from the prior fiscal year's 18%. This indicates a slowdown in the company's core business growth, which likely contributed to investor concerns regarding future performance.
2. Reduced Fiscal Year 2027 Subscription Revenue per Client Outlook: The company's outlook included a projected 7% decline in subscription revenue per client for fiscal year 2027, estimating it at $51.8K. This suggests potential pressure on the average revenue generated from each client, impacting future profitability.
Show more
Stock Movement Drivers
Fundamental Drivers
The -43.9% change in PHR stock from 10/31/2025 to 2/20/2026 was primarily driven by a -45.1% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.64 | 12.71 | -43.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 450 | 463 | 3.0% |
| P/S Multiple | 3.0 | 1.6 | -45.1% |
| Shares Outstanding (Mil) | 60 | 60 | -0.7% |
| Cumulative Contribution | -43.9% |
Market Drivers
10/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| PHR | -43.9% | |
| Market (SPY) | 1.1% | 30.4% |
| Sector (XLV) | 8.7% | 31.9% |
Fundamental Drivers
The -52.9% change in PHR stock from 7/31/2025 to 2/20/2026 was primarily driven by a -55.0% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 26.96 | 12.71 | -52.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 435 | 463 | 6.6% |
| P/S Multiple | 3.7 | 1.6 | -55.0% |
| Shares Outstanding (Mil) | 59 | 60 | -1.8% |
| Cumulative Contribution | -52.9% |
Market Drivers
7/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| PHR | -52.9% | |
| Market (SPY) | 9.4% | 34.3% |
| Sector (XLV) | 20.8% | 25.8% |
Fundamental Drivers
The -55.3% change in PHR stock from 1/31/2025 to 2/20/2026 was primarily driven by a -59.5% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 28.46 | 12.71 | -55.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 405 | 463 | 14.3% |
| P/S Multiple | 4.1 | 1.6 | -59.5% |
| Shares Outstanding (Mil) | 58 | 60 | -3.5% |
| Cumulative Contribution | -55.3% |
Market Drivers
1/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| PHR | -55.3% | |
| Market (SPY) | 15.6% | 40.2% |
| Sector (XLV) | 8.2% | 26.4% |
Fundamental Drivers
The -66.1% change in PHR stock from 1/31/2023 to 2/20/2026 was primarily driven by a -78.1% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 37.49 | 12.71 | -66.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 262 | 463 | 76.6% |
| P/S Multiple | 7.5 | 1.6 | -78.1% |
| Shares Outstanding (Mil) | 53 | 60 | -12.3% |
| Cumulative Contribution | -66.1% |
Market Drivers
1/31/2023 to 2/20/2026| Return | Correlation | |
|---|---|---|
| PHR | -66.1% | |
| Market (SPY) | 75.9% | 41.5% |
| Sector (XLV) | 23.1% | 28.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PHR Return | -23% | -22% | -28% | 9% | -33% | -26% | -77% |
| Peers Return | -32% | -57% | -2% | -13% | -22% | -18% | -84% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 0% | 83% |
Monthly Win Rates [3] | |||||||
| PHR Win Rate | 42% | 42% | 42% | 50% | 25% | 0% | |
| Peers Win Rate | 37% | 30% | 50% | 43% | 37% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| PHR Max Drawdown | -26% | -67% | -62% | -22% | -39% | -30% | |
| Peers Max Drawdown | -37% | -62% | -30% | -44% | -28% | -27% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, DOCS, VEEV, AMWL, GDRX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/20/2026 (YTD)
How Low Can It Go
| Event | PHR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -84.6% | -25.4% |
| % Gain to Breakeven | 550.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -51.4% | -33.9% |
| % Gain to Breakeven | 105.7% | 51.3% |
| Time to Breakeven | 217 days | 148 days |
Compare to TDOC, DOCS, VEEV, AMWL, GDRX
In The Past
Phreesia's stock fell -84.6% during the 2022 Inflation Shock from a high on 2/9/2021. A -84.6% loss requires a 550.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Phreesia (PHR)
AI Analysis | Feedback
Square for medical offices.
OpenTable for doctor's office check-ins.
TurboTax for healthcare check-ins.
AI Analysis | Feedback
Here are Phreesia's major products and services:- Patient Intake Platform: A comprehensive digital platform that streamlines patient registration, check-in, and data collection processes for healthcare providers.
- Payment Processing: Facilitates secure and convenient collection of patient payments, including co-pays, deductibles, and outstanding balances.
- Patient Engagement Solutions: Offers tools like appointment reminders, patient surveys, and digital forms to enhance communication and patient experience.
- Clinical Support Solutions: Provides tools for collecting patient-reported data and integrating it into electronic health records to support clinical workflows.
- Life Sciences Solutions: Enables pharmaceutical companies and clinical research organizations to identify, recruit, and engage patients for clinical trials.
AI Analysis | Feedback
Phreesia (PHR) primarily sells its healthcare technology solutions to other companies, specifically healthcare provider organizations.
Phreesia's public filings, such as its annual 10-K reports, do not disclose any individual customer or group of affiliated customers that account for 10% or more of its total revenue. This indicates a diverse and broad customer base rather than a reliance on a few "major" named customer companies. As such, no specific customer companies with their symbols can be listed as "major customers."
Therefore, while specific major customer names are not publicly available, Phreesia's customers are drawn from the following categories of healthcare organizations:
- Physician Practices and Medical Groups: These customers range from small independent clinics to large multi-specialty physician organizations. Phreesia's platform helps them streamline patient intake, improve workflows, and manage patient engagement.
- Hospitals and Health Systems: These are integrated networks that include multiple hospitals, outpatient clinics, and other healthcare facilities. Phreesia provides solutions to enhance patient experience and operational efficiency across their networks.
- Other Healthcare Facilities: This broad category encompasses various specialized care providers such as urgent care centers, behavioral health clinics, dental practices, and ambulatory surgery centers, all benefiting from Phreesia's digital patient intake and engagement tools.
AI Analysis | Feedback
- Amazon.com, Inc. (AMZN)
- Stripe, Inc. (Private Company)
- Fidelity National Information Services, Inc. (FIS)
AI Analysis | Feedback
Chaim Indig, Chief Executive Officer and Board MemberSince co-founding Phreesia in 2005, Chaim Indig has helped revolutionize the patient intake experience. Under his leadership, Phreesia has established a broad national footprint and developed strategic partnerships with large healthcare companies. Prior to founding Phreesia, he held key roles at Spotfire and OLAP@Work.
Balaji Gandhi, Chief Financial OfficerBalaji Gandhi leverages over 25 years of executive experience in overseeing Phreesia's financial operations and investor relations. Prior to joining Phreesia in 2019, he served as Chief Financial Officer of Madaket Inc., a cloud-based healthcare SaaS company. He also held leadership roles at companies including Press Ganey and Fresenius Medical Care, and spent more than a decade as an investment research analyst in the healthcare services market at firms such as Deutsche Bank and Oppenheimer & Co., Inc.
Evan Roberts, President, Provider SolutionsEvan Roberts co-founded Phreesia in 2005 and leads the company's efforts to bring value to its clients, overseeing ongoing operations and procedures. He previously served as Chief Technology Officer and as Vice President, Customer Solutions. Before co-founding Phreesia, Evan was a senior sales engineer at Spotfire, where he helped penetrate new markets and developed innovative applications.
David Linetsky, President of Network SolutionsDavid Linetsky is responsible for cultivating Phreesia's partnerships with life sciences companies, advocacy groups, government agencies, and other organizations. He has worked at Phreesia for more than a decade, holding key leadership roles including Vice President of Analytics and Insights, and Vice President of Finance. Prior to Phreesia, David worked in academia as a researcher and instructor in biotechnology, mathematics, and philosophy.
Allison Hoffman, General CounselAs Phreesia's General Counsel, Allison Hoffman manages the company's Legal, Compliance, Risk, Privacy, and Security teams, bringing over 25 years of legal and people-management experience. Before Phreesia, she served as Chief Legal and Administrative Officer for Intersection, a digital technology company. She also oversaw the legal and human resources departments for Martha Stewart Living Omnimedia, culminating in oversight of the company's sale.
AI Analysis | Feedback
Here are the key risks to Phreesia's business:- Cybersecurity Incidents and Data Privacy: Phreesia faces a significant risk from cybersecurity incidents and the need to maintain data privacy and security. The company has experienced such incidents in the past, including one impacting its ConnectOnCall product in 2024. Future incidents could disrupt business operations, harm the company's reputation, lead to economic loss, and expose them to legal penalties and liability, especially given the sensitive nature of the healthcare data they handle.
- Highly Competitive and Evolving Healthcare Industry: Phreesia operates in a very competitive industry characterized by rapidly changing technology standards, evolving regulatory requirements, and shifting client needs. Increased market saturation and competition from electronic health record (EHR) and practice management (PM) systems could negatively impact Phreesia's business and operating results.
- Regulatory Compliance with Healthcare and Data Privacy Laws: The company is subject to a complex and extensive framework of healthcare laws, as well as data privacy and security laws and regulations. Non-compliance with these laws could lead to substantial fines, penalties, lawsuits, adverse publicity, and a loss of customer trust, which would materially and adversely affect their business, prospects, financial condition, and results of operations.
AI Analysis | Feedback
The aggressive expansion and improvement of patient intake, engagement, and payment functionalities within major Electronic Health Record (EHR) platforms.
AI Analysis | Feedback
Phreesia (PHR) has an addressable market of approximately $24 billion across its main product and service segments in the U.S.. This market size includes the impact of the AccessOne acquisition.
- Subscription-based revenue: approximately $6.3 billion (U.S.).
- Payment solutions: approximately $9.1 billion (U.S.). This figure includes the implied provider financing market attributable to the AccessOne acquisition, which is expected to expand Phreesia's addressable market by roughly $6 billion.
- Network solutions: approximately $8.2 billion (U.S.).
AI Analysis | Feedback
Phreesia (PHR) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:
- Growth in Average Healthcare Services Clients (AHSCs): Phreesia continues to expand its client base, with expectations to reach approximately 4,500 Average Healthcare Services Clients (AHSCs) in fiscal year 2026. This consistent growth in the number of clients directly contributes to overall revenue expansion.
- Increase in Total Revenue per AHSC through Client Monetization: The company is focused on increasing the revenue generated from each existing client. This involves the cross-selling of newer provider add-on solutions and securing larger initial solution bundles with new clients. Phreesia anticipates total revenue per AHSC to increase in fiscal 2026 compared to fiscal 2025.
- Expansion of Network Solutions: Phreesia's Network Solutions segment is gaining momentum and is a significant contributor to the acceleration of average revenue per client. This area is specifically highlighted by analysts as a growth driver.
- Strategic Acquisition of AccessOne: The acquisition of AccessOne is a notable driver, projected to add approximately $35 million in annualized revenue and expand Phreesia's total addressable market by about $6 billion. The transaction is expected to close in the third or early fourth quarter of Phreesia's fiscal year 2026.
- Launch and Growth of New and AI-driven Products: Phreesia is investing in and rolling out new solutions, including AI-driven products like Voice AI. These new offerings are designed to improve medication adherence and enhance the overall patient and provider experience, beginning to generate revenue and contributing to future growth.
AI Analysis | Feedback
Share Repurchases
Phreesia has a stock repurchase program in place, but it does not obligate the company to repurchase a specified number or dollar value of shares, and the program may be modified, suspended, or discontinued at any time. As of the available information, there is no indication of significant dollar amounts of share repurchases made over the last 3-5 years.
Share Issuance
- As of March 7, 2025, Phreesia had 58,772,448 shares of common stock outstanding.
- As of March 6, 2024, there were 56,387,472 shares of common stock outstanding.
- As of March 17, 2023, there were 53,355,050 shares of common stock outstanding.
Outbound Investments
- Phreesia announced in September 2025 a definitive agreement to acquire AccessOne Parent Holdings, Inc. for $160 million in cash. The transaction is expected to close in the third or early fourth quarter of Phreesia's fiscal year 2026.
- In 2023, Phreesia acquired Access (likely Access eForms) and MediFind, both for undisclosed amounts.
- In December 2021, Phreesia acquired Insignia Health for $35 million.
Capital Expenditures
- Phreesia projects capital expenditures of $47 million for fiscal year 2026, $57 million for fiscal year 2027, $65 million for fiscal year 2028, $74 million for fiscal year 2029, and $84 million for fiscal year 2030, all estimated at 10% of revenue.
- The company's strategic focus for capital allocation includes investing in scalable, high-value products that drive patient and provider outcomes, with artificial intelligence (AI) being a central area for future product development and operational enhancements.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Phreesia Earnings Notes | 12/16/2025 | |
| Now Is Not The Time To Buy Phreesia Stock | 12/10/2025 | |
| Day 6 of Gains Streak for Phreesia Stock with 18% Return (vs. 29% YTD) [8/28/2025] | 08/29/2025 | |
| Why Phreesia Stock Moved: PHR Stock Has Lost 60% Since 2021 Fiscal End, Primarily Due To Unfavorable Change In Price To Sales Multiple (P/S) | 08/08/2025 | |
| PHR Dip Buy Analysis | 07/10/2025 | |
| Phreesia (PHR) Valuation Ratios Comparison | 05/15/2025 | |
| Phreesia (PHR) Operating Cash Flow Comparison | 02/17/2025 | |
| Phreesia (PHR) Net Income Comparison | 02/16/2025 | |
| Phreesia (PHR) Operating Income Comparison | 02/15/2025 | |
| Phreesia (PHR) Revenue Comparison | 02/13/2025 | |
| ARTICLES | ||
| Stocks Trading At 52-Week Low | 02/03/2026 | |
| Phreesia Stock To $12? | 12/10/2025 | |
| PHR Stock Up 18% after 6-Day Win Streak | 08/29/2025 |
Trade Ideas
Select ideas related to PHR.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -14.6% | -14.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.5% | 19.5% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 9.7% | 9.7% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -39.4% | -39.4% | -40.1% |
| 01022026 | CORT | Corcept Therapeutics | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 4.6% | 4.6% | -9.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.08 |
| Mkt Cap | 0.8 |
| Rev LTM | 719 |
| Op Inc LTM | 37 |
| FCF LTM | 123 |
| FCF 3Y Avg | 125 |
| CFO LTM | 236 |
| CFO 3Y Avg | 202 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.8% |
| Rev Chg 3Y Avg | 8.5% |
| Rev Chg Q | 5.1% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Mgn LTM | 4.2% |
| Op Mgn 3Y Avg | -1.6% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 17.9% |
| CFO/Rev 3Y Avg | 16.4% |
| FCF/Rev LTM | 10.3% |
| FCF/Rev 3Y Avg | 9.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.8 |
| P/S | 1.4 |
| P/EBIT | 4.0 |
| P/E | 9.5 |
| P/CFO | 8.6 |
| Total Yield | 1.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.2% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -18.3% |
| 3M Rtn | -29.0% |
| 6M Rtn | -42.1% |
| 12M Rtn | -55.1% |
| 3Y Rtn | -58.3% |
| 1M Excs Rtn | -18.8% |
| 3M Excs Rtn | -37.6% |
| 6M Excs Rtn | -48.0% |
| 12M Excs Rtn | -69.2% |
| 3Y Excs Rtn | -126.9% |
Price Behavior
| Market Price | $12.71 | |
| Market Cap ($ Bil) | 0.8 | |
| First Trading Date | 07/18/2019 | |
| Distance from 52W High | -61.0% | |
| 50 Days | 200 Days | |
| DMA Price | $15.17 | $22.69 |
| DMA Trend | down | down |
| Distance from DMA | -16.2% | -44.0% |
| 3M | 1YR | |
| Volatility | 58.4% | 48.3% |
| Downside Capture | 428.13 | 199.81 |
| Upside Capture | 61.36 | 91.15 |
| Correlation (SPY) | 24.4% | 39.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.08 | 1.63 | 1.71 | 1.67 | 1.02 | 1.50 |
| Up Beta | 1.98 | 1.44 | 1.75 | 1.91 | 0.74 | 1.10 |
| Down Beta | 0.62 | -1.17 | -0.83 | 0.88 | 0.69 | 1.24 |
| Up Capture | 36% | 107% | 120% | 67% | 102% | 388% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 7 | 20 | 28 | 58 | 121 | 369 |
| Down Capture | 613% | 518% | 356% | 255% | 146% | 112% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 21 | 33 | 67 | 126 | 375 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PHR | |
|---|---|---|---|---|
| PHR | -56.3% | 48.4% | -1.55 | - |
| Sector ETF (XLV) | 8.6% | 17.3% | 0.32 | 26.5% |
| Equity (SPY) | 13.5% | 19.4% | 0.53 | 39.8% |
| Gold (GLD) | 74.5% | 25.6% | 2.15 | -0.9% |
| Commodities (DBC) | 7.2% | 16.9% | 0.25 | 10.9% |
| Real Estate (VNQ) | 7.1% | 16.7% | 0.24 | 23.9% |
| Bitcoin (BTCUSD) | -30.6% | 44.9% | -0.68 | 18.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PHR | |
|---|---|---|---|---|
| PHR | -30.3% | 59.2% | -0.37 | - |
| Sector ETF (XLV) | 7.6% | 14.5% | 0.34 | 32.1% |
| Equity (SPY) | 13.4% | 17.0% | 0.62 | 45.5% |
| Gold (GLD) | 22.6% | 17.1% | 1.08 | 6.0% |
| Commodities (DBC) | 10.9% | 19.0% | 0.46 | 5.7% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 37.5% |
| Bitcoin (BTCUSD) | 7.2% | 57.1% | 0.35 | 23.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PHR | |
|---|---|---|---|---|
| PHR | -6.3% | 58.9% | 0.08 | - |
| Sector ETF (XLV) | 11.3% | 16.5% | 0.57 | 33.3% |
| Equity (SPY) | 16.1% | 17.9% | 0.77 | 43.4% |
| Gold (GLD) | 14.8% | 15.6% | 0.79 | 5.0% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 11.5% |
| Real Estate (VNQ) | 7.0% | 20.7% | 0.30 | 37.0% |
| Bitcoin (BTCUSD) | 67.8% | 66.7% | 1.07 | 22.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/8/2025 | -23.3% | -17.0% | -16.0% |
| 9/4/2025 | -9.9% | -18.4% | -25.4% |
| 5/28/2025 | -6.6% | 3.3% | 12.0% |
| 3/12/2025 | 6.9% | 21.8% | 0.8% |
| 12/9/2024 | 11.6% | 18.5% | 23.3% |
| 9/4/2024 | 6.3% | -3.5% | -8.7% |
| 5/30/2024 | -11.2% | -7.3% | -3.0% |
| 3/14/2024 | 4.8% | 4.0% | 0.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 12 | 13 |
| # Negative | 11 | 9 | 8 |
| Median Positive | 6.9% | 13.3% | 8.5% |
| Median Negative | -9.9% | -8.4% | -19.1% |
| Max Positive | 21.2% | 35.7% | 51.3% |
| Max Negative | -23.3% | -33.5% | -40.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 10/31/2025 | 12/09/2025 | 10-Q |
| 07/31/2025 | 09/05/2025 | 10-Q |
| 04/30/2025 | 05/28/2025 | 10-Q |
| 01/31/2025 | 03/13/2025 | 10-K |
| 10/31/2024 | 12/09/2024 | 10-Q |
| 07/31/2024 | 09/05/2024 | 10-Q |
| 04/30/2024 | 05/31/2024 | 10-Q |
| 01/31/2024 | 03/15/2024 | 10-K |
| 10/31/2023 | 12/06/2023 | 10-Q |
| 07/31/2023 | 09/07/2023 | 10-Q |
| 04/30/2023 | 06/01/2023 | 10-Q |
| 01/31/2023 | 03/23/2023 | 10-K |
| 10/31/2022 | 12/09/2022 | 10-Q |
| 07/31/2022 | 09/08/2022 | 10-Q |
| 04/30/2022 | 06/03/2022 | 10-Q |
| 01/31/2022 | 03/31/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Linetsky, David | President, Network Solutions | Spouse | Sell | 12192025 | 16.49 | 94 | 1,550 | 161,384 | Form |
| 2 | Hui, Yvonne | Principal Accounting Officer | Direct | Sell | 12192025 | 16.25 | 426 | 6,922 | 486,038 | Form |
| 3 | Gandhi, Balaji | Chief Financial Officer | Direct | Sell | 10212025 | 22.36 | 885 | 19,790 | 2,196,764 | Form |
| 4 | Hoffman, Allison C | General Counsel & Secretary | Direct | Sell | 10212025 | 22.36 | 1,241 | 27,750 | 3,035,242 | Form |
| 5 | Indig, Chaim | Chief Executive Officer | Direct | Sell | 10212025 | 22.36 | 3,163 | 70,728 | 28,009,818 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.